Outsourcing Pharma

SEPTEMBER 9, 2021

Nucala, a monoclonal antibody indicated for patients with chronic rhinosinusitis with nasal polyps, has been approved by the Food and Drug Administration.

Drugs 91

Drugs Antibody Drug Delivery 91

pharmaphorum

APRIL 29, 2021

The 3 rd Annual Blood-Brain Barrier Summit is dedicated to helping drug developers enhance drug delivery across the Blood-Brain Barrier (BBB) to enable effective treatments for neurodegenerative diseases. New for this year we also explore the mechanisms of SARS-CoV-2 brain entry. DOWNLOAD THE PROGRAM HERE.

Drug Delivery 52

Drug Delivery Engineer Drugs Antibody 52

pharmaphorum

MARCH 15, 2022

Sarclisa is a CD38-directed antibody that is currently approved as an intravenous therapy for relapsed multiple myeloma in combination with either Bristol-Myers Squibb’s Pomalyst (pomalidomide) plus dexamethasone or Amgen’s Kyprolis (carfilzomib) plus dexamethasone. .

Trials 97

Trials Sales Drug Delivery Antibody 97

Delveinsight

MARCH 2, 2021

HitGen & UPPTHERA Collaborate for Drug Delivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. 3-day Conference | June 28-30, 2021.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

pharmaphorum

JANUARY 12, 2021

Vaxart said in November it had completed enrolment in a phase 1 trial of its oral COVID-19 vaccine VXA-CoV2-1, having reported viral load reduction and antibody responses in a COVID-19 hamster challenge model. ImmunityBio’s vaccine design drives both antibody and T-cells to the spike (S) protein and nucleocapsid (N) protein.

Licensing 119

Licensing Licensing Vaccine Vaccination 119

XTalks

NOVEMBER 3, 2021

The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer.

Life Science 52

Life Science Drug Delivery Systems Vaccine Vaccination 52

Pharmaceutical Technology

APRIL 16, 2023

But with the advent of injection site absorption enhancers, drug delivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. For them, intravenous infusion in a hospital setting is the only option. References 1.

Protein 130

Protein Containment Drug Delivery Drugs 130

Roots Analysis

MARCH 16, 2022

In order to promote the use of exosomes in various therapeutic applications including targeted drug delivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Our Social Media Platform. Web: [link].

Marketing 59

Marketing Manufacturing Drug Delivery Drug Delivery Systems 59

pharmaphorum

OCTOBER 11, 2022

The results were disappointing, with only a minority of patients getting the intranasal regimen showing signs of SARS-CoV-2 antigen-specific antibody responses in the mucosa, which according to the researchers “rarely” exceeded the levels one would see after a COVID-19 infection.

Vaccine 116

Vaccine Vaccination Immune Response Development 116

XTalks

SEPTEMBER 16, 2024

Ocrevus Zunovo uses Halozyme Therapeutics’ Enhanze drug delivery technology , which enhances absorption by temporarily increasing the permeability of the subcutaneous tissue. The enzyme rHuPH20 enables rapid dispersion of the drug into the bloodstream. The global multiple sclerosis (MS) drug market expects growth from $21.16

FDA Approval 59

FDA Approval Drug Delivery Antibody Drugs 59

pharmaphorum

JUNE 30, 2021

AdCOVID was able to stimulate antibodies that bound the SARS-CoV-2 spike protein and were able to neutralise the virus, but not in sufficient quantities and in too few patients.

Vaccine 98

Vaccine Vaccination Trials Immune Response 98

The Pharma Data

JANUARY 6, 2021

Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found h e re.

Medicine 52

Medicine Antibody Protein In-Vitro 52

pharmaphorum

DECEMBER 18, 2020

With the aim of achieving a higher quality of life for those with unfavourable prognoses, this project, funded by Innovate UK, the UK’s innovation agency, brings together partners with a wealth of experience and specialist know-how in the areas of nanoparticle development, drug delivery and bioimaging.

Drug Delivery 52

Drug Delivery Medicine Clinical Trials Clinical Trials 52

pharmaphorum

DECEMBER 23, 2020

Roche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta that is easier and cheaper to administer to patients – and also provides a defence against biosimilar competition. The post Roche claims EU okay for Herceptin/Perjeta combination Phesgo appeared first on.

Sales 52

Sales Drug Delivery Antibody Production 52

Roots Analysis

FEBRUARY 16, 2023

As projected by Roots Analysis, antibodies will have the highest share in this market. Further, majority of capacity is available with service providers headquartered in Asia-Pacific. This trend is likely to continue in the future.

Drug Delivery 52

Drug Delivery Production Marketing Antibody 52

Roots Analysis

SEPTEMBER 13, 2023

Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Development 40

Development Antibody Protein Drug Delivery Systems 40

Roots Analysis

MAY 24, 2024

In the dynamic landscape of the healthcare sector, the evolution of drug delivery systems plays a significant role in transforming the management of chronic diseases. These devices reduce injection anxiety, and are useful for patients who prefer a hands-free drug delivery experience.

Drug Delivery 40

Drug Delivery Containment Contamination Production 40

Roots Analysis

OCTOBER 13, 2023

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action.

Drugs 40

Drugs Antibody RNA Genetics 40

Delveinsight

NOVEMBER 29, 2020

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv).

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

The Pharma Data

OCTOBER 20, 2020

” Mr. Bliss joins TLC following interim roles in cellular therapy, drug delivery and combination therapy where he led efforts to confirm research outcomes and partner the various technologies. Earlier in his career, he ran business-development functions at Amgen and Baxter.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

Roots Analysis

FEBRUARY 26, 2024

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research You may also be interested in the following titles: Continuous Manufacturing (Small Molecules and Biologics) Market Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Antibody Discovery Services and Platforms Market Our Social Media Platform Web: (..)

Drug Delivery Systems 52

Drug Delivery Systems Marketing Drug Delivery Development 52

Delveinsight

JULY 30, 2021

However, the Crohn’s disease market space experienced strides of research and developments imbibed with continuous innovation in terms of drug delivery platforms, MoAs, and RoAs with an end goal to minimize the numbers of patients experiencing no-response from the treatment.

Marketing 74

Marketing Drug Delivery Development Clinical Trials 74

Roots Analysis

JUNE 6, 2024

Key Growth Drivers Autoinjectors Market Ease of Use: The benefits of using autoinjectors over conventional methods of parenteral drug delivery are widely recognized by healthcare industry professionals as well as end-users.

Medicine 40

Medicine Drug Delivery Manufacturing Marketing 40

Roots Analysis

FEBRUARY 14, 2023

This can be attributed to the fact that liposomes can actively target tumor tissues when used in combination with antibodies. Majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy. These platforms have created an opportunity for the product developers to share their innovative ideas in this domain.

Development 52

Development Manufacturing Drug Delivery Systems Contract Manufacturing 52

The Pharma Data

JANUARY 17, 2021

Evox uses its proprietary DeliverEX technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system.

Life Science 40

Life Science Drug Delivery Engineer Drugs 40

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Our Social Media Platform. Web: [link].

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

The Pharma Data

JANUARY 24, 2021

Faricimab is the first bispecific antibody designed for the eye. Faricimab is the first investigational bispecific antibody designed for the eye. This high treatment burden can lead to under-treatment and potentially less than optimal vision outcomes. chief medical officer and head of Global Product Development. About faricimab.

Antibody 40

Antibody Medicine Development Drug Delivery 40

The Pharma Data

JUNE 26, 2021

Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients. Faricimab is the first investigational bispecific antibody designed for the eye.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

Roots Analysis

MARCH 24, 2022

You may also be interested in the following titles: Continuous Manufacturing (Small Molecules and Biologics) Market Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Antibody Discovery Services and Platforms Market. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

The Pharma Data

JANUARY 17, 2021

“This marks another significant milestone as we continue to leverage our polypeptide nano-particle technology for siRNA drug delivery to advance our pipeline of oncology therapeutic candidates,” said Patrick Lu , Ph.D., the founder, President and CEO of Sirnaomics. Chief Medical Officer. About Sirnaomics, Inc.

Gene Expression 52

Gene Expression Trials Development Production 52

The Pharma Data

MAY 15, 2023

If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye. Roche’s Chief Medical Officer and Head of Global Product Development. “If

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. 1 4 About Vabysmo ® ( faricimab ) Vabysmo is the first bispecific antibody approved for the eye.

Antibody 40

Antibody In-Vitro Development Trials 40

XTalks

MAY 30, 2024

The FDA’s decision under the Prescription Drug User Fee Act (PDUFA) is anticipated by June 21, 2024. Vyvgart Hytrulo is a subcutaneous formulation that combines efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20.

FDA Approval 40

FDA Approval Immune Response Trials Drug Delivery 40

Roots Analysis

AUGUST 8, 2023

Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drug delivery have been highlighted in the figure.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs In-Vivo 52

Roots Analysis

FEBRUARY 26, 2024

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52